8
Figure 1a-e, supplement b c a d +fMLP PH-Akt-GFP Anti-PIP 3 antibody unstimulated (min ) + fMLP (100 nM) Akt S473P-Akt T308P-Akt e 0 0.5 1 1.5 2 4
Figure 1a-e, supplement
b
c
a
d
+fMLP
PH-Akt-GFP Anti-PIP3 antibody
unstimulated
(min)
+ fMLP (100 nM)
Akt
S473P-Akt
T308P-Akt
e
0 0.5 1 1.5 2 4
0
10
20
30
40
1 2 3 4 5 6
Figure 1f, supplement
0
10
20
30
40
50
1 2 3 4 5 6
(min)
+ fMLP (100 nM)
0 0.5 1 1.5 2 4
f
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
PH-Akt-GFP DiD
Ratio (PH-Akt-GFP/DiD)
Overlaya
b
Fig. 2a-b, supplement
c
Fig. 2c, supplement
Figure 3a, supp
a
HL-60 + 50 nM wort
Akt
S473P-Akt
T308P-Akt
HL-60 +fM
LP
HL-60
b
Figure 3b-d, supplement+ 50 nM
wort
+ 200 M LY
+ 200 nM w
ort
+ 400 M LY
+ 200 nM wort
c
d
+ 20 nM w
ort
+ 50 M LY
+ 50 nM w
ort
+ 200M LY
+ 200 nM w
ort
+ 400M LY
+ 20 nM w
ort
+ 50M LY
0
20
40
60
80
100
120
1 2 3 4 5 6 7
S4
73
P-A
kt
(%)
0
20
40
60
80
100
120
T3
08
P-A
kt
(%)
HL-60
Re
lati
ve
le
ve
l o
f R
ela
tiv
e l
ev
el
of
Figure 4, supplement
a
HL
-60
+ w
ort
2 min 6 min 10 min
HL
-60
+ w
ort
Paths
3
b c
1
2 4
0
50
100
150
HL-60HL-60+ 50 nM
wort
+ 200 nM w
ort+ fMLP
a b
c
Figure 5, supplement
PLB-985 + 200 M LY 294002 + 30 nM wortmannin
Human blood neutrophils0.1 1 10 1000
0
2000
4000C
ell
Nu
mb
er
Log [fMLP] (nM)
